Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

MUC16 suppresses human and murine innate immune responses.

Felder M, Kapur A, Rakhmilevich AL, Qu X, Sondel PM, Gillies SD, Connor J, Patankar MS.

Gynecol Oncol. 2019 Jan 6. pii: S0090-8258(18)31537-3. doi: 10.1016/j.ygyno.2018.12.023. [Epub ahead of print]

PMID:
30626487
2.

Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites.

Morris ZS, Guy EI, Werner LR, Carlson PM, Heinze CM, Kler JS, Busche SM, Jaquish AA, Sriramaneni RN, Carmichael LL, Loibner H, Gillies SD, Korman AJ, Erbe AK, Hank JA, Rakhmilevich AL, Harari PM, Sondel PM.

Cancer Immunol Res. 2018 Jul;6(7):825-834. doi: 10.1158/2326-6066.CIR-17-0353. Epub 2018 May 10.

PMID:
29748391
3.

Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.

Rakhmilevich AL, Felder M, Lever L, Slowinski J, Rasmussen K, Hoefges A, Van De Voort TJ, Loibner H, Korman AJ, Gillies SD, Sondel PM.

J Immunol. 2017 Feb 15;198(4):1575-1584. doi: 10.4049/jimmunol.1601255. Epub 2017 Jan 6.

4.

In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.

Morris ZS, Guy EI, Francis DM, Gressett MM, Werner LR, Carmichael LL, Yang RK, Armstrong EA, Huang S, Navid F, Gillies SD, Korman A, Hank JA, Rakhmilevich AL, Harari PM, Sondel PM.

Cancer Res. 2016 Jul 1;76(13):3929-41. doi: 10.1158/0008-5472.CAN-15-2644. Epub 2016 May 6.

5.

Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages.

Shi Y, Felder MA, Sondel PM, Rakhmilevich AL.

Mol Immunol. 2015 Aug;66(2):208-15. doi: 10.1016/j.molimm.2015.03.008. Epub 2015 Mar 28.

6.

Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.

Qu X, Felder MA, Perez Horta Z, Sondel PM, Rakhmilevich AL.

Int Immunopharmacol. 2013 Dec;17(4):1141-7. doi: 10.1016/j.intimp.2013.10.019. Epub 2013 Nov 4.

7.

Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM.

Cancer Immunol Immunother. 2013 Aug;62(8):1303-13. doi: 10.1007/s00262-013-1430-x. Epub 2013 May 10.

8.

Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.

Van De Voort TJ, Felder MA, Yang RK, Sondel PM, Rakhmilevich AL.

J Immunother. 2013 Jan;36(1):29-40. doi: 10.1097/CJI.0b013e3182780f61.

9.

Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG.

Alderson KL, Luangrath M, Elsenheimer MM, Gillies SD, Navid F, Rakhmilevich AL, Sondel PM.

Cancer Immunol Immunother. 2013 Apr;62(4):665-75. doi: 10.1007/s00262-012-1372-8. Epub 2012 Nov 15.

10.

Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM.

J Immunol. 2012 Sep 1;189(5):2656-64. doi: 10.4049/jimmunol.1200934. Epub 2012 Jul 27.

11.

T-cell-independent antitumor effects of CD40 ligation.

Rakhmilevich AL, Alderson KL, Sondel PM.

Int Rev Immunol. 2012 Aug;31(4):267-78. doi: 10.3109/08830185.2012.698337. Review.

12.

Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects.

Rakhmilevich AL, Baldeshwiler MJ, Van De Voort TJ, Felder MA, Yang RK, Kalogriopoulos NA, Koslov DS, Van Rooijen N, Sondel PM.

Cancer Immunol Immunother. 2012 Oct;61(10):1683-97. Epub 2012 Mar 6.

13.

Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy.

Soto BL, Hank JA, Darjatmoko SR, Polans AS, Yanke EM, Rakhmilevich AL, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM.

Int Immunopharmacol. 2011 Nov;11(11):1877-86. doi: 10.1016/j.intimp.2011.07.019. Epub 2011 Aug 18.

14.

Melanoma-induced suppression of tumor antigen-specific T cell expansion is comparable to suppression of global T cell expansion.

Russ AJ, Xu K, Wentworth L, Alam S, Meyers JV, Macklin MD, Rakhmilevich AL, Rajamanickam V, Suresh M, Cho CS.

Cell Immunol. 2011;271(1):104-9. doi: 10.1016/j.cellimm.2011.06.011. Epub 2011 Jun 17.

15.

The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model.

Soto BL, Hank JA, Van De Voort TJ, Subramanian L, Polans AS, Rakhmilevich AL, Yang RK, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2011 May;60(5):731-8. doi: 10.1007/s00262-011-0971-0. Epub 2011 Feb 22.

16.

Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.

Buhtoiarov IN, Neal ZC, Gan J, Buhtoiarova TN, Patankar MS, Gubbels JA, Hank JA, Yamane B, Rakhmilevich AL, Reisfeld RA, Gillies SD, Sondel PM.

J Leukoc Biol. 2011 Apr;89(4):625-38. doi: 10.1189/jlb.0710422. Epub 2011 Jan 19.

17.

Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.

Johnson EE, Buhtoiarov IN, Baldeshwiler MJ, Felder MA, Van Rooijen N, Sondel PM, Rakhmilevich AL.

J Immunother. 2011 Jan;34(1):76-84. doi: 10.1097/CJI.0b013e318200b28a.

18.

Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.

Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, Mahvi DA, Rakhmilevich AL.

Immunology. 2011 Feb;132(2):226-39. doi: 10.1111/j.1365-2567.2010.03357.x. Epub 2010 Oct 13.

19.

Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.

Johnson EE, Yamane BH, Buhtoiarov IN, Lum HD, Rakhmilevich AL, Mahvi DM, Gillies SD, Sondel PM.

Clin Cancer Res. 2009 Aug 1;15(15):4875-84. doi: 10.1158/1078-0432.CCR-09-0110. Epub 2009 Jul 28.

20.

Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia.

Wu QL, Buhtoiarov IN, Sondel PM, Rakhmilevich AL, Ranheim EA.

J Immunol. 2009 Jun 1;182(11):6771-8. doi: 10.4049/jimmunol.0801847.

21.

Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules.

Buhtoiarov IN, Rakhmilevich AL, Lanier LL, Ranheim EA, Sondel PM.

J Immunol. 2009 Feb 15;182(4):1940-53. doi: 10.4049/jimmunol.0800443.

22.

Intratumoral immunocytokine treatment results in enhanced antitumor effects.

Johnson EE, Lum HD, Rakhmilevich AL, Schmidt BE, Furlong M, Buhtoiarov IN, Hank JA, Raubitschek A, Colcher D, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2008 Dec;57(12):1891-902. doi: 10.1007/s00262-008-0519-0. Epub 2008 Apr 26.

23.

CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.

Rakhmilevich AL, Buhtoiarov IN, Malkovsky M, Sondel PM.

Cancer Immunol Immunother. 2008 Aug;57(8):1151-60. doi: 10.1007/s00262-007-0447-4. Epub 2008 Jan 24.

PMID:
18214476
24.

Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.

Buhtoiarov IN, Sondel PM, Eickhoff JC, Rakhmilevich AL.

Immunology. 2007 Mar;120(3):412-23. Epub 2006 Dec 8.

25.

Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha.

Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL.

Immunology. 2006 Jun;118(2):261-70.

26.

In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.

Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL.

J Leukoc Biol. 2006 Jun;79(6):1181-92. Epub 2006 Mar 24.

PMID:
16565324
27.

Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects.

Buhtoiarov IN, Lum HD, Berke G, Sondel PM, Rakhmilevich AL.

J Immunol. 2006 Jan 1;176(1):309-18.

28.

CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.

Buhtoiarov IN, Lum H, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL.

J Immunol. 2005 May 15;174(10):6013-22.

29.
30.

Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.

Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov IN, Lum HE, Imboden M, Hank JA, Lode HN, Reisfeld RA, Gillies SD, Sondel PM.

Clin Cancer Res. 2004 Jul 15;10(14):4839-47.

31.

NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.

Neal ZC, Imboden M, Rakhmilevich AL, Kim KM, Hank JA, Surfus J, Dixon JR, Lode HN, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2004 Jan;53(1):41-52. Epub 2003 Sep 18.

PMID:
14504825
32.

Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model.

Shi F, Rakhmilevich AL, Heise CP, Oshikawa K, Sondel PM, Yang NS, Mahvi DM.

Mol Cancer Ther. 2002 Sep;1(11):949-57.

33.

Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor.

Rakhmilevich AL, Imboden M, Hao Z, Macklin MD, Roberts T, Wright KM, Albertini MR, Yang NS, Sondel PM.

Clin Cancer Res. 2001 Apr;7(4):952-61.

34.

The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.

Imboden M, Murphy KR, Rakhmilevich AL, Neal ZC, Xiang R, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Res. 2001 Feb 15;61(4):1500-7.

35.

Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer.

Oshikawa K, Rakhmilevich AL, Shi F, Sondel PM, Yang N, Mahvi DM.

Hum Gene Ther. 2001 Jan 20;12(2):149-60.

PMID:
11177552
36.

Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.

Turner JG, Rakhmilevich AL, Burdelya L, Neal Z, Imboden M, Sondel PM, Yu H.

J Immunol. 2001 Jan 1;166(1):89-94.

37.
38.

In vivo particle-mediated gene transfer for cancer therapy.

Rakhmilevich AL, Yang NS.

Methods Mol Med. 2000;35:331-44. doi: 10.1385/1-59259-086-1:331.

PMID:
21390815
39.
40.

Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy.

Rakhmilevich AL, Timmins JG, Janssen K, Pohlmann EL, Sheehy MJ, Yang NS.

J Immunother. 1999 Mar;22(2):135-44.

PMID:
10093038
41.
42.

Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12.

Rakhmilevich AL, Janssen K, Turner J, Culp J, Yang NS.

Hum Gene Ther. 1997 Jul 20;8(11):1303-11.

PMID:
9295125
43.

Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors.

Rakhmilevich AL, Turner J, Ford MJ, McCabe D, Sun WH, Sondel PM, Grota K, Yang NS.

Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6291-6.

44.
45.

Gamma delta T cells and acute primary Toxoplasma gondii infection in mice.

Sayles PC, Rakhmilevich AL, Johnson LL.

J Infect Dis. 1995 Jan;171(1):249-52.

PMID:
7798675
46.

[Effect of total exogenous hyperthermia on the activity of natural killer cells].

Solov'ev AS, Rakhmilevich AL.

Patol Fiziol Eksp Ter. 1995 Jan-Mar;(1):38-9. Russian.

PMID:
7610006
47.
50.

Elimination of CD4+ T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2.

Rakhmilevich AL, North RJ.

Cancer Immunol Immunother. 1994 Feb;38(2):107-12.

PMID:
7905789

Supplemental Content

Loading ...
Support Center